Eli Lilly and Co (HAM:LLY) NonCurrent Deferred Liabilities: €0 Mil (As of Mar. 2026)


HAM:LLY Eli Lilly and Co HAM:LLY
96 GF Score
Price €1,038.00
GF Value €1,243.42
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co NonCurrent Deferred Liabilities?

Eli Lilly and Co HAM:LLY -1.78% 96 NonCurrent Deferred Liabilities is €0 Mil as of Mar. 2026. GuruFocus rates HAM:LLY with a GF Score™ of 96/100 and a GF Value™ of €1,243.42 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Eli Lilly and Co's non-current deferred liabilities for the quarter that ended in Mar. 2026 was €0 Mil.

Eli Lilly and Co NonCurrent Deferred Liabilities Related Terms

Eli Lilly and Co NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co NonCurrent Deferred Liabilities Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,534.33 0.00 0.00 0.00 0.00

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HAM:LLY
96GF Score
Eli Lilly and Co HAM:LLY
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €0 Mil mean?
Eli Lilly and Co (HAM:LLY) has a NonCurrent Deferred Liabilities of €0 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's NonCurrent Deferred Liabilities too high?
Eli Lilly and Co's current NonCurrent Deferred Liabilities is €0 Mil. Overall, Eli Lilly and Co has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's NonCurrent Deferred Liabilities compare to JNJ and ABBV?
Eli Lilly and Co's NonCurrent Deferred Liabilities of €0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current NonCurrent Deferred Liabilities is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (HAM:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is €1,243.42, compared to a current price of €1,038.00 — trading 16.5% below its estimated fair value. The current NonCurrent Deferred Liabilities is €0 Mil. Eli Lilly and Co's overall GF Score™ is 96/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Eli Lilly and Co (HAM:LLY), the current NonCurrent Deferred Liabilities is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (HAM:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of €1,038.00 is trading 16.5% below its estimated GF Value™ of €1,243.42. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for HAM:LLY:

  • NonCurrent Deferred Liabilities: €0 Mil
  • GF Value™: €1,243.42 vs. price of €1,038.00 (16.5% below fair value)
  • GF Score™: 96/100 with 6 warning signs

No single metric tells the full story. See the HAM:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
96GF Score

Get the complete analysis for HAM:LLY

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1,038.00
Price
€1,243.42
GF Value